Mycosis fungoides (MF) is the most common clinicopathologic subtype of primary cutaneous T-cell lymphoma.
Objective:
The therapy of MF is highlighted in this overview.
Results and Conclusions:
Skin-directed MF therapies include topical corticosteroids, nitrogen mustard, carmustine (BCNU), topical bexarotene gel, imiquimod cream, radiotherapy, total skin electron beam therapy, and phototherapy. Systemic therapies include extracorporeal photopheresis, interferon, oral bexarotene, denileukin diftitox, monoclonal antibodies and cytokine therapy, and other systemic chemotherapy. Finally, some investigative therapeutic modalities are presented.
Get full access to this article
View all access options for this article.
References
1.
WillemzeRJaffeESBurgG. WHO-EORTC classification for cutaneous lymphomas. Blood, Feb 3 2005. [Epub ahead of print].
2.
BarankinBFreimanA. Misnomers in dermatology. J Cutan Med Surg2005;9:284–8.
3.
GirardiMHealdPWWilsonLD. The pathogenesis of mycosis fungoides. N Engl J Med2004;350:1978–88.
4.
ZackheimHS. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther2003;16:283–7.
5.
ZackheimHSKashani-SabetMAminS. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol1998;134:949–54.
6.
KimYH. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther2003;16:288–98.
7.
KimYHMartinezGVargheseAHoppeRT. Topical nitrogen mustard in the management of mycosis fungoides: Update of the Stanford experience. Arch Dermatol2003;139:165–73.
8.
LeeLAFritzKAGolitzL. Second cutaneous malignancies in patients with mycosis fungoides treated with topical nitrogen mustard. J Am Acad Dermatol1982;7:590–8.
9.
ZackheimHS. Topical carmustine (BCNU) in the treatment of mycosis fungoides. Dermatol Ther2003;16:299–302.
10.
LiuHLKimYH. Bexarotene gel: A Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol2002;138:398–9.
11.
BrenemanDDuvicMKuzelT. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol2002;138:325–32.
12.
DeethsMJChapmanJTDellavalleRP. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol2005;52:275–80.
JonesGWKacinskiBMWilsonLD. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol2002;47:364–70.
15.
RampinoMRagonaRMonettiU. Total skin electron beam therapy in mycosis fungoides. Our experience from 1985 to 1999. Radiol Med (Torino)2002;103:108–14.
16.
YsebaertLTrucGDalacS. Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys2004;58:1128–34.
17.
BaronEDStevensSR. Phototherapy for cutaneous T-cell lymphoma. Dermatol Ther2003;16:303–10.
18.
QuerfeldCRosenSTKuzelTM. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol2005;141:305–11.
19.
GhodsiSZHallajiZBalighiK. Narrow-band UVB in the treatment of early stage mycosis fungoides: Report of 16 patients. Clin Exp Dermatol2005;30:376–8.
20.
NisticoSCostanzoASaracenoRChimentiS. Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis fungoides. Br J Dermatol2004;151:877–9.
21.
ZicJA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther2003;16:337–46.
22.
WilsonLDJonesGWKimD. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol2000;43(1 Pt 1):54–60.
23.
VonderheidEC. Photopheresis: Current and future perspectives. J Cutan Med Surg2003;(4 Suppl):1–24.
24.
KuzelTMRoenigkHHJrSamuelsonE. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol1995;13:257–63.
25.
HuberMAKunzi-RappKStaibGScharffetter-KochanekK. Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy. J Am Acad Dermatol2004;50:475–6.
26.
SinghFLebwohlMG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: A case series. J Am Acad Dermatol2004;51:570–3.
27.
TalpurRApisarnthanaraxNWardSDuvicM. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (Ontak). Leuk Lymphoma2002;43:121–6.
28.
OlsenEDuvicMFrankelA. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol2001;19:376–88.
29.
RookAHKuzelTMOlsenEA. Cytokine therapy of cutaneous T-cell lymphoma: Interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am2003;17:1435–48, ix.
30.
LundinJHagbergHReppR. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood2003;101:4267–72.
31.
KnoxSHoppeRTMaloneyD. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood1996;87:893–9.
32.
KuzelTM. Systemic chemotherapy for the treatment of mycosis fungoides and Sezary syndrome. Dermatol Ther2003;16:355–61.
33.
ZackheimHSKashani-SabetMMcMillanA. Low-dose methotrexate to treat mycosis fungoides: A retrospective study in 69 patients. J Am Acad Dermatol2003;49:873–8.
34.
ZinzaniPLBalivaGMagagnoliM. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients. J Clin Oncol2000;18:2603–6.
35.
SoligoDIbaticiABertiE. Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen. Bone Marrow Transplant2003;31:663–6.
36.
KellyWKRichonVMO'ConnorO. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res2003;9(10 Pt 1):3578–88.
37.
WysockaMBenoitBMNewtonS. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood2004;104:4142–9.
